Study of LAU-7b for the Treatment of Long COVID in Adults
Status:
Active, not recruiting
Trial end date:
2024-08-31
Target enrollment:
Participant gender:
Summary
ESSOR is a double-blind, placebo-controlled study of the orally-administered antiviral and
inflammation-controlling LAU-7b for the treatment of adults with Long COVID and moderate to
severe symptoms.